Genomic Expression, Inc.
PrivateLast Round
Seed
Nov 15, 2024
Total Funding Raised
$12.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Genomic Expression, Inc. operates in Healthcare & Life Sciences and is based in Beverly, Massachusetts. Its latest recorded funding round was a Seed round in November 2024.
Genomic Expression, Inc. is a biotechnology company that provides RNA-based diagnostic services and develops AI-driven platforms for personalized cancer treatment and drug discovery.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Usage-Based SaaS, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genomic Expression, Inc. Comparables
Compare Genomic Expression, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cofactor Genomics | 84% | |
| Rna Diagnostics Inc. | 79% | |
| BostonGene | 76% |
For institutional investors. Book with your work email.
Genomic Expression, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 15, 2024 | ||||
| Convertible Debt | Sep 1, 2024 | ||||
| Crowdfunding | Nov 1, 2023 | ||||
| Convertible Debt | Nov 1, 2021 | ||||
| Grant | Jan 3, 2018 | ||||
Seed | May 1, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Genomic Expression, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Innovation Fund Denmark | Grant |
| Pipeline Angels | Seed |
| Eurostars SME programme | Grant |
| Harvard Business School Alumni Angels Association | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 181% MoM.
- Apr 2, 2026
Monthly visitors increased 76% MoM.
For institutional investors. Book with your work email.
Genomic Expression, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Genomic Expression, Inc.'s valuation, stock price, and market status.
Is Genomic Expression, Inc. a public or private company?
Genomic Expression, Inc. is a private company.
What is the current stock price of Genomic Expression, Inc.?
Genomic Expression, Inc. is a private company, so its shares have no public market price. Caplight tracks Genomic Expression, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Genomic Expression, Inc. worth (valuation)?
Valuation information for Genomic Expression, Inc. is not publicly available.
Can I buy Genomic Expression, Inc. stock?
Genomic Expression, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Genomic Expression, Inc.'s last funding round?
Genomic Expression, Inc.'s most recent funding round was Seed on November 15, 2024.
Who are the main investors in Genomic Expression, Inc.?
Key investors in Genomic Expression, Inc. include National Cancer Institute, Innovation Fund Denmark, Pipeline Angels, Eurostars SME programme, Harvard Business School Alumni Angels Association.
Will Genomic Expression, Inc. IPO soon?
No public IPO plans have been announced for Genomic Expression, Inc..
How can I track Genomic Expression, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Genomic Expression, Inc.'s shares on secondary markets.